The medication adherence specialist is joining IT4Anxiety, a project focused on dealing with anxiety in patients with mental disorders, via technology.
A leader from the patient recruitment specialist discusses the industry’s ongoing challenges with patient population diversity, and potential solutions.
While strides have been made recruiting more representative patient populations, more can and should be done, according to an Oracle Health Sciences leader.
The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.
This month’s announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
With a specific focus on clinical trials involving treatments for rare diseases, Orphan Reach seeks to build upon the services that conventional CROs offer.
In its latest diversity, equity and inclusion report, Global Genes offers insight into obstacles faced by rare-disease patients from minority communities.
On February 23, five days ahead of the day of rare-disease awareness, OSP’s Rare and Orphan Diseases webinar will share insights from top industry experts.
In this second of a two-part series, experts from the clinical research organization share thoughts on how data management technology, personnel, and partnerships have evolved.
Vision, part of the company’s Clinical Maestro platform of software-as-a-solution applications, enables study teams to manage clinical vendor oversight.
An expert from the CRO discusses the role real-world data plays in developing therapies, with benefits ranging from speeding recruitment to decreasing costs.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
A leader from Elligo Health Research (a SCOPE 2022 exhibitor ) discusses flaws in traditional recruitment approaches and offers up some fresh new ideas.
A leader from the RBQM solutions specialists offers a preview of his SCOPE 2022 presentation on tools suited to decentralized trial design and management.
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
One of the finalists for the 2022 Participant Engagement Award (saluting patient recruitment and retention solution) will be announced as winner at SCOPE.
An expert from the CRO discusses unique challenges associated with running clinical trials that stretch across national boarders and how to conquer them.
The Medicines and Healthcare Products Regulatory Agency has released proposals to bolster trials legislation, asking citizens for input on the suggestions.
Regulatory bodies in the European Union have launched an initiative to develop the region as a focal point for clinical research and to better integrate clinical research in the European health system.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
A leader from Oracle Health Sciences shares insights on how drug development and research pros collaborated to overcome formidable challenges this year.
The healthcare company has gifted $1m to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
According to a leader from the virtual engagement solutions company, gaps in trial communications can be improved with the intelligent use of technology.
A survey on perceptions toward the decentralized clinical trial format, conducted by Climedo, shows the industry is aware of the benefits but faces barriers
The organizations have issued an in-depth look on issues impacting inclusivity, why change is needed, and potential solutions for increasing trial diversity.
Patient data from the clinical solutions company indicates that gains in recruitment of Black participants is outpacing that of patients from other groups.
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
An expert from the decentralized study solutions company shares perspectives on the importance of inclusivity and solutions that could improve representation.
During OSP’s November 17 online event, a group of experts will offer insights, advice, and examples of solutions that put patients at the center of studies.
The respiratory care specialist shares perspective on issues faced by respiratory studies, and how to overcome such obstacles to get therapies to market.
Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.
RSG Arrive is intended to increase clinical trial participation by offering ground transport, plane rides, hotels, visa procurement, and other services.
The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.
An expert from the IRB and study solutions firm explains how advanced analytics can lead to several benefits, including shortened trial startup timelines.
An expert from the CRO explains the evolution of data technologies put to use in clinical studies and offers advice on how to best make them work in trials.
Conducted by patient services specialist Greenphire, the survey checks in with contract research organizations and shows how they are approaching obstacles.
A leader from Firma Clinical Research advises that while using RWD can be daunting, putting the data to use can lead to a number of notable advantages.
The cancer-centric pharma firm will collaborate with the Philadelphia-based cancer center to pinpoint new indications and biomarkers for its drug candidate.
A logistics leader from the CRO offers advice on navigating borders, cultures, regulatory issues and other important considerations on worldwide studies.
According to a leader from the health engagement solutions firm, intelligent use of technology tools can add patient-centricity and realism to a study.
Swift Skin and Wound is a digital imaging technology designed to support decentralized clinical trials conducted to evaluate skin and wound treatments.
Two experts from the contract research organization offer advice on planning and executing clinical studies with the unique needs of such patients in mind.
A physician assistant from Hawthorne Effect shares how she and other trained health professionals contribute their knowledge and talents to in-home studies.
The decentralized trial tech firm will work with Applied VR on five studies testing the viability of virtual-reality therapy in treating pain patients.
An executive from the digital therapeutics specialist discusses the clinical trial landscape, and how clinical care can yield a number of important benefits.
A leader from Veeva Systems shares perspective on what factors are impacting clinical trial data management, and how the industry can adapt to the changes.
The National Institute on Aging has launched Outreach Pro, an online tool aimed to help connect with underrepresented populations for Alzheimer’s trials.
